bamlanivimab and etesevimab together

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What are the criteria for use and recommended dose of bamlanivimab and etesevimab together for the treatment of COVID-19?

The recommended dose in adults is bamlanivimab 700 mg and etesevimab 1400 mg given together as a single IV infusion and administered as soon as possible after testing positive for SARS-CoV-2 and within 10 days of symptom onset.

US_cFAQ_BAM_ETE010_X1_DOSE_CRITERIA_FOR_TREATMENT_COVID-19
US_cFAQ_BAM_ETE010_X1_DOSE_CRITERIA_FOR_TREATMENT_COVID-19
en-US

Bamlanivimab and Etesevimab Emergency Use Authorization

Bamlanivimab and etesevimab have not been approved, but have only been authorized for emergency use by Food and Drug Administration (FDA) for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the bamlanivimab and etesevimab under Section 564(b)(1)(C) of the Act, 21 U.S.C. 360bbb-3, unless the authorization is terminated or revoked sooner.1,2   

Bamlanivimab and etesevimab are authorized to be administered together in adults and pediatric patients, including neonates, who are at high risk for progression to severe coronavirus disease 2019 (COVID-19), including hospitalization or death for

  • the treatment of mild to moderate COVID-19, or
  • post-exposure prophylaxis of COVID-19.1,2    

For information on the authorized use of bamlanivimab and etesevimab together and mandatory requirements under the emergency use authorization (EUA), please review the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients/Caregivers at www.LillyAntibody.com. 1,2    

Limitations of Authorized Use

Combined Frequency of Variants Resistant to Bamlanivimab and Etesevimab

Bamlanivimab and etesevimab are not authorized for treatment of mild to moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.1

FDA’s determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.1

FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility and CDC regional variant frequency data available at:  https://covid.cdc.gov/covid-data-tracker/#variant-proportions.1

Use in Patients Who Are Hospitalized or Who Require Oxygen Due to COVID-19

Bamlanivimab and etesevimab are not authorized for use in patients 2 years and older who are hospitalized due to COVID-19.1

The reasons for hospital admission may be different and the threshold for hospital admission may be lower for neonates, young infants and toddlers with COVID-19 compared to older children and adults. The authorization allows for young children (i.e., birth to 2 years of age) who are hospitalized with mild to moderate COVID-19 at the time of treatment to receive bamlanivimab and etesevimab.1

Bamlanivimab and etesevimab are not authorized for use in patients, regardless of age who require

  • oxygen therapy and/or respiratory support due to COVID-19, OR
  • an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity.1

Treatment with bamlanivimab and etesevimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation.1

Bamlanivimab and Etesevimab Fact Sheet for Healthcare Providers

Contraindications

There are no known contraindications for bamlanivimab and etesevimab together.1

Bamlanivimab and Etesevimab Dosing

Patient Selection

The following medical conditions or other factors may place adults and pediatric patients, including neonates, at higher risk for progression to severe COVID-19:1 

  • Older age (for example age ≥65 years of age)
  • <1 year old
  • Obesity or being overweight
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease (including congenital heart disease) or hypertension
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
  • Sickle cell disease
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of bamlanivimab and etesevimab under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the Centers for Disease Control and Prevention (CDC) website: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Healthcare providers should consider the benefit-risk for an individual patient.1 

Recommended Dosage

The dosage for treatment of COVID-19 in adults (18 years and older) and pediatric patients (<18 years and weighing at least 40 kg) is 700-mg bamlanivimab and 1400-mg etesevimab.1

The dosage for pediatric patients weighing less than 40 kg will vary depending on body weight

  • >20 kg to <40 kg: 350 mg bamlanivimab and 700 mg etesevimab
  • >12 kg to 20 kg: 175 mg bamlanivimab and 350 mg etesevimab
  • 1 kg to 12 kg: 12 mg/kg bamlanivimab and 24 mg/kg etesevimab1

For treatment of COVID-19, bamlanivimab and etesevimab should be administered together as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.1

Dosage Adjustment in Specific Populations

No dosage adjustment is recommended based on renal or mild hepatic impairment, during pregnancy or while lactating, or in geriatric patients.

  • Based on population PK analysis, there is no difference in PK of bamlanivimab and etesevimab in patients with mild hepatic impairment compared to patients with normal hepatic function.1
  • Bamlanivimab and etesevimab have not been studied in patients with moderate or severe hepatic impairment.1

Bamlanivimab and Etesevimab Available Clinical Data

BLAZE-1 SARS-CoV-2 Permitted Testing

Any type of direct SARS-CoV-2 testing was permitted in the BLAZE-1 clinical trial, provided it was an FDA-approved test to allow for maximum flexibility at clinical trial sites.3

Direct SARS-CoV-2 Viral Testing

Viral testing determines COVID-19 infection by detecting SARS-CoV-2 nucleic acid or antigen from the respiratory system (such as nasal or oral swabs or saliva) or blood. Therefore, viral tests directly test acute infection.4

SARS-CoV-2 Antibody Testing

The FDA has not authorized using antibody tests to diagnose SARS-CoV-2 infection, the virus that causes COVID-19. Antibody tests do not directly test for acute viral infection. Antibody tests can help determine whether the individual being tested was previously infected.4

Healthcare Setting for Patient Selection and Treatment Initiation

Bamlanivimab and etesevimab are not authorized for use in patients 2 years and older who are hospitalized due to COVID-19.1

Bamlanivimab and etesevimab are not authorized for use in patients, regardless of age who require

  • oxygen therapy and/or respiratory support due to COVID-19, OR
  • an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity.1

Treatment with bamlanivimab and etesevimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation.1

However, if patient selection criteria are met for a patient who is hospitalized, but not due to COVID-19, bamlanivimab and etesevimab may be considered. 

Bamlanivimab and etesevimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.1

BLAZE-1 Patient Monitoring

During the BLAZE-1 clinical trial, patients were monitored during the infusion as well as for at least 2 hours after completion of the infusion.3

Immediately prior to the infusion and 30 minutes after completion of the infusion, the following vital signs were assessed

  • body temperature
  • pulse rate
  • blood pressure
  • respiratory rate
  • SpO2 at rest, and
  • supplemental oxygen flow rate, FiO2 if known, and method of delivery, if applicable. 3

During the infusion, only record pulse rate, BP and SpO2.3

Automation was permitted to be used to measure vital signs.3

References

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1Fact sheet for healthcare providers. Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. US Food and Drug Administration (FDA). 2022.

2United States Food and Drug Administration. Bamlanivimab and etesevimab FDA Emergency Use Authorization letter. Issued January 24, 2022. Accessed January 25, 2022. http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf

3Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632-644. http://dx.doi.org/10.1001/jama.2021.0202

4Overview of Testing for SARS-CoV-2 (COVID-19). Center for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Published October 21, 2020. Accessed November 18, 2020.

Date of Last Review: January 26, 2022


Contact Lilly

Call Us

If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.

Daily Live Support: 9am to 7pm ET.
After Hours: Call Back Support Available

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical